Scalper1 News
Shares of Eli Lilly (LLY) jumped to a more than 14-year high Thursday as the company presented more evidence that its diabetes drug Jardiance reduces death from heart failure. At the annual European Association for the Study of Diabetes, Lilly and partner Boehringer Ingelheim presented details on the massive Empa-Reg Outcome Trial studying the long-term cardiovascular effects of Jardiance, which they first headlined last month. Lilly and Ingelheim Scalper1 News
Scalper1 News